SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-
Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that our project
“Research and Development of Next-Generation Focused Ultrasound Therapy System for
Intractable Cancer” has been selected for the PCA (Product Commercialization Alliance)
phase of the Deep Tech Startup Support Program implemented by New Energy and Industrial
Technology Development Organization (NEDO).

The adoption of this program will further accelerate the development of our “next-generation
HIFU (High-Intensity Focused Ultrasound) therapy device”.

We will continue to promote our business in order to realize the wish we put in our company
name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer
Patients and their Families.”.